explore -WSS

explore

author：focus 2025-08-26 02:49:13 - browse：7967

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Popular nasal decongestant doesn't actually relieve congestion

Wikipedia

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Why did Pfizer dish out millions for a Super Bowl ad?

The Readout: Gilead, Bernie Sanders, and other pharma news

Vaccine advisory panel ACIP left half staffed by HHS

Walmart eyes Medicare Advantage provider ChenMed

Private equity could exacerbate cardiology's overuse problem, experts fear

knowledge

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Senators start work on Medicare physician payment reform

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

PEPFAR is under serious threat — and so is global health

Tori Bowie and the unacceptable rates of Black maternal death

Biogen Alzheimer’s drug launch off to slow start

ChatGPT in medicine: STAT answers readers' burning questions

How digital tools helped lower hypertension in marginalized patients

Affirmative action in medical school literally saved lives

WATCH: Why do bright lights make us see spots?

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Hospitals consider fixing cancer drug shortages on their own

Doctors' information doesn't help them choose wisely when sick

Regeneron agrees to White House price limits on anti

Pig kidney works a record two months in donated body

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

Wikipedia

entertainment

hotspot